PE20110560A1 - NEW DERIVATIVES OF TRIAZOLO [4,3-a] PYRIDINE, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NEW USE, PARTICULARLY AS MET INHIBITORS - Google Patents

NEW DERIVATIVES OF TRIAZOLO [4,3-a] PYRIDINE, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NEW USE, PARTICULARLY AS MET INHIBITORS

Info

Publication number
PE20110560A1
PE20110560A1 PE2011000048A PE2011000048A PE20110560A1 PE 20110560 A1 PE20110560 A1 PE 20110560A1 PE 2011000048 A PE2011000048 A PE 2011000048A PE 2011000048 A PE2011000048 A PE 2011000048A PE 20110560 A1 PE20110560 A1 PE 20110560A1
Authority
PE
Peru
Prior art keywords
triazolo
new
medicines
pyridine
pharmaceutical compositions
Prior art date
Application number
PE2011000048A
Other languages
Spanish (es)
Inventor
Eric Bacque
Dominique Damour
Conception Nemecek
Patrick Nemecek
Sylvie Wentzler
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0804084A external-priority patent/FR2933980B1/en
Priority claimed from FR0900245A external-priority patent/FR2941229B1/en
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20110560A1 publication Critical patent/PE20110560A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE Ra ES H, HALOGENO, ARILO, HETEROARILO, HETEROARILO, ENTRE OTROS; RB ES H, ALQUILO, -COO-ALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[6-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-3-ILSULFANIL)-1,3-BENZOTIAZOL-2-IL]UREA; 6-[(6-YODO[1,2,4]TRIAZOLO[4,3-a]PIRIDIN-3-IL)SULFANIL]-1,3-BENZOTIAZOL-2-AMINA; N-(6-{[6-(1-METIL-1H-PIRAZOL-4-IL)[1,2,4]TRIAZOLO[4,3-a]PIRIDIN-3-IL]SULFANIL}-1,3-BENZOTIAZOL-2-IL)CICLOPROPANOCARBOXAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE LA PROTEINA QUINASA MET Y DE SUS FORMAS MUTANTES, UTILES EN EL TRATAMIENTO DE CANCERREFERRING TO A COMPOUND OF FORMULA I, WHERE Ra IS H, HALOGEN, ARYL, HETEROARILO, HETEROARILO, AMONG OTHERS; RB IS H, ALKYL, -COO-ALKYL, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: N- [6 - ([1,2,4] TRIAZOLO [4,3-a] PYRIDIN-3-ILSULFANIL) -1,3-BENZOTHIAZOL-2-IL] UREA; 6 - [(6-IODINE [1,2,4] TRIAZOLO [4,3-a] PYRIDIN-3-IL) SULFANIL] -1,3-BENZOTHIAZOL-2-AMINE; N- (6 - {[6- (1-METHYL-1H-PYRAZOLE-4-IL) [1,2,4] TRIAZOLO [4,3-a] PYRIDIN-3-IL] SULFANIL} -1,3- BENZOTHIAZOL-2-IL) CYCLOPROPANOCARBOXAMIDE; AMONG OTHERS. ALSO REFERRED TO A PREPARATION PROCESS AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF THE ACTIVITY OF PROTEIN KINASE MET AND ITS MUTANT FORMS, USEFUL IN THE TREATMENT OF CANCER

PE2011000048A 2008-07-18 2009-07-16 NEW DERIVATIVES OF TRIAZOLO [4,3-a] PYRIDINE, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NEW USE, PARTICULARLY AS MET INHIBITORS PE20110560A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0804084A FR2933980B1 (en) 2008-07-18 2008-07-18 NOVEL TRIAZOLO®4,3-A! PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS
FR0900245A FR2941229B1 (en) 2009-01-21 2009-01-21 NOVEL TRIAZOLO®4,3-A! PYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS

Publications (1)

Publication Number Publication Date
PE20110560A1 true PE20110560A1 (en) 2011-08-29

Family

ID=41550767

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000048A PE20110560A1 (en) 2008-07-18 2009-07-16 NEW DERIVATIVES OF TRIAZOLO [4,3-a] PYRIDINE, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NEW USE, PARTICULARLY AS MET INHIBITORS

Country Status (19)

Country Link
US (1) US20110263594A1 (en)
EP (1) EP2310366A2 (en)
JP (1) JP2011528337A (en)
KR (1) KR20110039558A (en)
CN (1) CN102159543A (en)
AR (1) AR072819A1 (en)
AU (1) AU2009272516A1 (en)
BR (1) BRPI0916464A2 (en)
CA (1) CA2730959A1 (en)
CL (1) CL2011000119A1 (en)
CO (1) CO6331463A2 (en)
EA (1) EA201170222A1 (en)
IL (1) IL210688A0 (en)
MA (1) MA32570B1 (en)
MX (1) MX2011000671A (en)
PE (1) PE20110560A1 (en)
TW (1) TW201008938A (en)
UY (1) UY31996A (en)
WO (1) WO2010007316A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
FR2966151B1 (en) * 2010-10-14 2012-11-09 Sanofi Aventis 6- (ALKYL- OR CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS
WO2012116237A2 (en) * 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CN105143228B (en) * 2013-05-10 2017-07-21 江苏豪森药业集团有限公司 [1,2,4] triazol [4,3 a] pyridine derivatives, its preparation method or its in application pharmaceutically
US20160108039A1 (en) * 2013-06-03 2016-04-21 Bayer Pharma Aktiengesellschaft Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN106489962B (en) * 2016-10-20 2019-02-22 贵州大学 One kind [1,2,4] triazole [4,3-a] pyridines sulfur-containing compound is preparing the application in insecticide
JP7414282B2 (en) 2017-12-07 2024-01-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン NSD family inhibitors and methods of treatment using them
EA202192575A1 (en) 2019-03-21 2022-01-14 Онксео DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR CANCER TREATMENT
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857371A (en) * 1954-09-10 1958-10-21 Eastman Kodak Co Benzothiazole azo diphenylamine compounds
EP0048555B1 (en) * 1980-08-27 1985-12-04 Glaxo Group Limited Amino-1,2,4-triazole derivatives, processes for their preparation and pharmaceutical compositions containing them
FR2601952B1 (en) * 1986-07-23 1988-11-25 Carpibem NOVEL AMINO ALKYL THIO DERIVATIVES OF TRIAZOLOPYRIDINE OR TRIAZOLOQUINOLINE, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM, USEFUL IN PARTICULAR AS ANTALGICS
US7008748B1 (en) * 2004-09-07 2006-03-07 Eastman Kodak Company Silver salt-toner co-precipitates and imaging materials
KR101412675B1 (en) * 2005-12-21 2014-07-03 얀센 파마슈티카 엔.브이. Triazolopyridazines as tyrosine kinase modulators
TW200900060A (en) * 2007-02-01 2009-01-01 Glaxo Group Ltd Chemical compounds
PA8792501A1 (en) * 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.

Also Published As

Publication number Publication date
EP2310366A2 (en) 2011-04-20
AR072819A1 (en) 2010-09-22
US20110263594A1 (en) 2011-10-27
TW201008938A (en) 2010-03-01
JP2011528337A (en) 2011-11-17
CN102159543A (en) 2011-08-17
MX2011000671A (en) 2011-04-11
AU2009272516A1 (en) 2010-01-21
WO2010007316A3 (en) 2010-04-29
CO6331463A2 (en) 2011-10-20
CA2730959A1 (en) 2010-01-21
BRPI0916464A2 (en) 2018-06-12
EA201170222A1 (en) 2011-08-30
KR20110039558A (en) 2011-04-19
IL210688A0 (en) 2011-03-31
WO2010007316A2 (en) 2010-01-21
UY31996A (en) 2010-02-26
MA32570B1 (en) 2011-08-01
CL2011000119A1 (en) 2011-06-17

Similar Documents

Publication Publication Date Title
PE20110560A1 (en) NEW DERIVATIVES OF TRIAZOLO [4,3-a] PYRIDINE, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NEW USE, PARTICULARLY AS MET INHIBITORS
PE20090370A1 (en) DERIVATIVES OF FUSED HETEROCYCLE AS KINASE INHIBITORS
PE20110545A1 (en) TRIAZOLOPYRIDINE COMPOUNDS AS JAK INHIBITORS
PE20120534A1 (en) PYRIMIDINES FUSED AS INHIBITORS OF Akt
PE20110572A1 (en) DERIVATIVES OF IMIDAZO [1,2-a] PYRIDINE AS MET INHIBITORS
PE20110411A1 (en) IMIDAZOPYRIDAZINE CARBONITRILES AS KINASE INHIBITORS
PE20080548A1 (en) DERIVATIVES OF [4,5 '] BIPYRIMIDINYL-6,4'-DIAMINE AS PROTEIN KINASE INHIBITORS
PE20090944A1 (en) BICYCLE PYRIMIDINES FUSED AS INHIBITORS OF THE PI3K / AKT VIA
PE20151249A1 (en) PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF JAK KINASES
SE0402735D0 (en) Novel compounds
PE20080893A1 (en) BICYCLIC TRIAZOLES AS MODULATORS OF PROTEIN KINASE
PE20090511A1 (en) IMIDAZOPYRIDINONES
PE20170189A1 (en) NEW DERIVATIVES OF PYRAZOLO PYRIMIDINE AND THEIR USE AS INHIBITORS OF MALT1
PE20170666A1 (en) 2- (MORFOLIN-4-IL) -1,7-NAPHTHYRIDINES
PE20080403A1 (en) FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
ECSP109953A (en) DERIVATIVES OF PIRIDAZINONA
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
EA201000092A1 (en) TRIPLE-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
PE20141855A1 (en) DISUSTITUTED BENZOTHENYL-PYRROLOTRIAZINES AND THEIR USES
EA201001368A1 (en) HETEROCYCLIC UREA DERIVATIVES AND METHODS OF THEIR APPLICATION-211
PE20090210A1 (en) COMPOUNDS DERIVED FROM PYRAZOLO PYRIMIDINE AS INHIBITORS OF JAK QUINASE
ATE514699T1 (en) SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVES AS KINASE INHIBITORS
UY29246A1 (en) NEW COMPOUNDS
PE20091116A1 (en) DERIVATIVES OF PYRIDINE AND PIRAZINE AS INHIBITORS OF TYROSINE KINASES
EA201000090A1 (en) Triple substituted derivatives of pyrimidine for the treatment of proliferative diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal